Table III.
Correlation between effectiveness of chemotherapy and baseline serum levels of tumor markers.
| Variables | N | CR + PR | NC + PD | χ2 | P-value |
|---|---|---|---|---|---|
| CYFRA 21-1 (ng/ml) | |||||
| <3.3 | 98 | 53 | 45 | ||
| ≥3.3 | 130 | 50 | 80 | 3.935 | 0.047a |
| CEA (ng/ml) | |||||
| <5.0 | 143 | 63 | 80 | ||
| ≥5.0 | 129 | 47 | 82 | 1.636 | 0.201 |
| CA 125 (U/ml) | |||||
| <35 | 135 | 69 | 66 | ||
| ≥35 | 107 | 34 | 73 | 0.710 | 0.791 |
| CA 19-9 (U/ml) | |||||
| <37 | 210 | 81 | 119 | ||
| ≥37 | 42 | 12 | 30 | 21.885 | <0.001a |
| NSE (ng/ml) | |||||
| <17 | 145 | 70 | 75 | ||
| ≥17 | 68 | 25 | 43 | 2.482 | 0.115 |
a
P<0.05. CYFRA 21-1, cytokeratin 19 fragment; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; NSE, neuron-specific enolase; CR, complete response; PR, partial response; NC, no change; PD, progressive disease.